The LRA is pleased to share news announced by Aurinia Pharmaceuticals of published results showing that the lupus treatment, voclosporin (Lupkynis) preserved kidney function up to three years among lupus nephritis. These results of the Phase 3, double-blind, placebo-controlled AURORA 2 extension study were published in the official peer-reviewed professional journal of the American College of Rheumatology Arthritis & Rheumatology.
The AURORA 2 extension study assessed the long-term safety and tolerability of voclosporin, compared with placebo, in combination with standard of care mycophenolate mofetil and low-dose glucocorticoids, to treat active lupus nephritis in adult patients who had completed one year of treatment in the Phase 3 AURORA 1 clinical trial. Voclosporin was well tolerated with no new or worsening safety issues. Clinical efficacy over three years of treatment was maintained, as observed by maintenance of lowered levels of the protein creatinine in the urine, sustained complete renal response and preserved kidney function. Study investigators concluded that these results suggest a positive benefit-risk profile for voclosporin in lupus nephritis patients.
Read Press Release from Aurinia Pharmaceuticals